Pentila

Quick links to important sections

Pentila

Method of action: Ophthalmologicals

Treatment option: Hypertension, Glaucoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pentila

Quick Facts

Property Description
Active Ingredient Levobunolol Hydrochloride
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class Non-selective Beta-Adrenergic Receptor Inhibitor (Beta-blocker)
Common Purpose Reduction of Elevated Intraocular Pressure (IOP)
Origin Synthetic

Pentila: Identity, Origin, and Pharmacological Class

The medicine known as Pentila is a prescription-only therapeutic product whose active component is the synthetic compound Levobunolol Hydrochloride. This substance is formally classified as a beta-adrenergic receptor inhibitor, placing it within the pharmacological class of beta-blockers. Levobunolol is distinctively characterized as a non-selective beta-adrenoceptor antagonist, a property that contributes to its comprehensive efficacy in pressure reduction, a benefit that is clinically recognized for its long-term management utility.

Composition and Topical Ophthalmic Form

Pentila is supplied as a sterile ophthalmic solution, designed exclusively for topical ophthalmic administration—meaning it is applied to the eye's surface as a liquid. This medicine is a single-ingredient product, where the Levobunolol Hydrochloride is dissolved in a specialized aqueous vehicle. The integrity of the sterile solution is crucial for achieving this localized therapeutic effect efficiently upon administration.

General Therapeutic Purpose and Mechanism Principle

The fundamental role of Levobunolol is that of an antiglaucoma agent. Its overarching purpose is to achieve a direct and sustained reduction of elevated intraocular pressure (IOP). Levobunolol is characterized by its consistent efficacy in lowering elevated IOP, positioning it as an established therapy for chronic open-angle glaucoma and ocular hypertension. The primary mechanism involves the drug acting as a sympatholytic agent to decrease the rate at which aqueous humor is produced by the eye, effectively slowing down the eye’s fluid generation.

What side effects are possible with Pentila?

Possible Side Effects and Safety Information

The safety profile of Pentila (Levobunolol Hydrochloride) encompasses both localized adverse reactions and potential systemic effects typical of the non-selective beta-blocker class, which may occur due to systemic absorption following topical administration.

Regulatory Classification of Adverse Reactions

Official regulatory documents classify adverse events by frequency and the body system affected. The most frequently documented events relate to the eyes:

Frequency Classification Officially Documented Effects
Very Common (ge 1/10) Eye irritation, Eye pain
Common (ge 1/100 to <1/10) Blepharitis, Conjunctivitis
Rare (ge 1/10,000 to <1/1,000) Transient ataxia, Iridocyclitis

Adverse reactions may affect other System-Organ Classes, including Cardiac Disorders (e.g., bradycardia, cardiac failure, hypotension), Respiratory Disorders (e.g., bronchospasm, dyspnoea), and Nervous System Disorders (e.g., headache, dizziness, confusion). Certain effects, such as depression or hypersensitivity reactions, are classified as Not Known (cannot be estimated from available data).

Serious Adverse Reactions and Population Notes

The official labeling highlights the risk of Serious Adverse Reactions (SARs), including severe cardiac events like overt cardiac failure and severe respiratory events such as bronchospasm, which are inherent to the systemic action of beta-blockers. Safety information also specifies considerations for certain populations:

  • Pediatric Patients: Safety and effectiveness have not been established in this population.
  • Diabetic Patients: The medication may mask the signs and symptoms of acute hypoglycemia.

Furthermore, the official safety documentation notes the potential for additive systemic effects when co-administered with oral beta-adrenergic blocking agents. The presence of sodium metabisulfite in the formulation is noted as a restriction, as it may cause allergic-type reactions, including asthmatic episodes, in susceptible individuals.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Pentila (a strong opioid pain reliever) is a medical emergency that can be fatal and requires immediate action. The most critical risk is severe, life-threatening respiratory depression (slowed or stopped breathing), which is the primary cause of death following overdose.

Clinical Manifestations of Overdose

Official regulatory information describes overdose by the triad of central nervous system (CNS) depression, respiratory depression, and miosis (pinpoint pupils). Other serious signs include stupor, coma, cyanosis (blue discoloration of skin due to lack of oxygen), and circulatory depression.

Overdose Risk and Immediate Action

Overdose risk is extremely high in individuals who are not opioid-tolerant, as life-threatening effects can occur even at low doses. Accidental ingestion of a single unit by a child can be fatal and is considered a high-priority risk in official labeling. Additionally, using this medication with other CNS depressants or certain enzyme inhibitors (CYP3A4 inhibitors) significantly increases the risk of fatal respiratory depression.

Immediate medical attention is required in the event of any suspected or known overdose. Regardless of the user’s conscious state or current symptoms, emergency assistance must be sought immediately. The immediate management includes establishing a patent airway, providing assisted or controlled ventilation, and administering an opioid antagonist to reverse the effects.

Therapeutic Uses of Pentila

What Pentila Treats: Main Uses and Benefits

Pentila (Levobunolol Hydrochloride) is commonly used as a therapeutic agent in the management of specific chronic conditions linked to organ-specific functional stress. Its application is considered relevant in addressing a key risk factor for potential vision loss. This medication is generally used to help with conditions presenting with systemic or localized discomfort.

The primary indications for Pentila include chronic open-angle glaucoma and ocular hypertension. These conditions are relevant in contexts where elevated pressure (IOP) inside the eye is a key clinical sign that often presents without pain or other noticeable symptoms that interfere with daily functioning. The drug’s consistent pressure-lowering effect is applied in scenarios where additional management of discomfort is required.

The main therapeutic benefit of using Pentila assists with maintaining functional stability and supports the goal of visual health preservation. By providing a reliable and sustained reduction of the pathological fluid pressure imbalance, the medication may assist with relieving the ongoing mechanical stress on the optic nerve. This targeted action contributes to slowing the progression of glaucoma, which may assist with the preservation of existing visual function, and supports general well-being during symptomatic phases.

“Pentila supports patients during episodes of heightened discomfort by assisting with the underlying physiological stressor.”


Quick Fact: Support for Elevated Pressure

Property Description
Targeted Sign Pathologically Elevated Intraocular Pressure (IOP)
Clinical Context Chronic maintenance therapy
Patient Benefit Goal Preservation of existing vision
Symptom Type Addressed Asymptomatic visual health threat

Regulatory References

  1. National Institutes of Health (NIH) DailyMed Label

Eligibility and Restrictions for Use

Who can and cannot use Pentila?

The eligibility profile for Pentila (Levobunolol Hydrochloride) is defined by official regulatory documents based on the drug's activity as a non-selective beta-blocker. These rules determine who is eligible to use the medicine and who must be excluded.


Populations Who Must Not Use Pentila (Contraindications)

The medicine is strictly contraindicated in several groups where use could pose severe systemic risks. This includes individuals with Bronchial Asthma or a history of the condition, Severe Chronic Obstructive Pulmonary Disease (COPD), and several severe cardiac conditions, such as Sinus Bradycardia, Overt Cardiac Failure, and Second or Third Degree Atrioventricular (AV) block. Use is also prohibited for patients with known hypersensitivity to the drug.


Conditional Use and Age-Related Rules

Official labeling specifies that the drug should be used with caution in patients with comorbidities such as Diabetes Mellitus, Thyroid Disorder, Peripheral Vascular Disease (like Raynaud's phenomenon), or Mild-to-Moderate COPD. For age groups, while use is established in adults, safety and efficacy have not been established for the pediatric population. During pregnancy, Pentila is generally not recommended unless clearly necessary, and mothers who are breastfeeding should consider cessation of nursing if treatment is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Pentila (Levobunolol Hydrochloride) is defined by its potential for systemic absorption as a non-selective beta-blocker, resulting in documented additive effects with other medicines.

Drug-Drug Interactions and Restrictions

Co-administration with any other systemic beta-adrenergic blocking agent or other topical ophthalmic beta-blocker is generally restricted or contraindicated. This is due to the potential for exaggerated systemic or ocular effects from additive beta-blockade.

Combining Pentila with Oral Calcium Channel Blockers (e.g., diltiazem, verapamil), Anti-Arrhythmics, or Digitalis Glycosides may lead to additive pharmacodynamic effects, including documented risks of hypotension and/or marked bradycardia.

Close observation is required when co-administering with Catecholamine-Depleting Drugs, such as Reserpine, due to the possibility of additive effects on heart rate and blood pressure, potentially causing postural hypotension.

Exposure and Administration Constraints

Co-administration with Phenothiazine-related compounds is associated with additive hypotensive effects, which is officially attributed to a documented inhibition of each other's metabolism that alters exposure.

For the proper administration of multiple topical eye medicines, a procedural constraint is specified: doses must be separated by several minutes to avoid the physical washout effect that could reduce Pentila's exposure. No formal interaction patterns are documented with food, alcohol, or herbal products.

Mechanism of Action

Pentila is a small molecule that functions as a highly selective, reversible competitive inhibitor of Janus Kinase 3 (JAK3), an enzyme predominantly expressed in hematopoietic cells.

Following cell membrane penetration, Pentila binds to the ATP-binding domain within the active site of JAK3. This interaction prevents the phosphorylation and subsequent activation of the kinase. Blocking JAK3 activation interrupts the signaling cascade initiated by various cytokine receptors (e.g., receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) that utilize the common gamma chain (gammac).

The resulting inhibition of JAK-STAT signal transduction prevents the downstream nuclear translocation of Signal Transducer and Activator of Transcription (STAT) proteins. This molecular cascade ultimately results in the transcriptional downregulation of genes critical for the proliferation, differentiation, and overall activity of specific immune cell subsets, thereby modulating the systemic physiological output of the immune system.

Dosage and Administration Information

The medicine known as Pentila (Levobunolol Hydrochloride) is administered exclusively via the topical ophthalmic route, applied as a sterile solution directly into the conjunctival sac of the affected eye(s). It is available in two concentrations: 0.5% and 0.25%. The usage pattern is determined by the concentration selected.

For the 0.5% solution, the standard starting dose is typically one to two drops once daily. This frequency may be increased to a maximum of one drop twice daily if required for more intensive pressure management, though dosages exceeding this limit are not typically associated with further efficacy. In contrast, the 0.25% solution is administered at a standard frequency of twice daily, with one or two drops per dose.

To ensure proper administration, specific procedural steps must be followed. If soft contact lenses are worn, they must be removed prior to instillation and may only be reinserted 15 minutes after the dose is applied. Following the drop's application, nasolacrimal occlusion or gently closing the eyelids for one to two minutes is utilized; this technique is defined to limit systemic exposure.

Usage is not recommended for the pediatric population due to a lack of safety and efficacy data. The medicine is generally not administered concurrently with other topical ophthalmic beta-adrenergic blocking agents. When used for angle-closure glaucoma, Pentila must be administered in conjunction with a miotic agent and not as a sole therapy. Treatment is established over time, with the pressure-lowering effect requiring assessment of intraocular pressure approximately four weeks after treatment begins.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pentila

Evidence for Use in Chronic Open-Angle Glaucoma

Research for Pentila was studied for its use, primarily involving Randomized Controlled Trials (RCTs). These studies monitored outcomes reflecting physiological strain inside the eye, specifically the change in Intraocular Pressure (IOP), in adult subjects with chronic open-angle glaucoma. These trials were often double-masked, comparing the medicine against a placebo or other active agents.

The findings describe patterns observed in the studies regarding changes measured in IOP. Comparative studies were also used in research exploring how IOP measurements compared against other agents, and contributes to the broader evidence landscape.

Evidence for Use in Ocular Hypertension

Pentila was studied for subjects diagnosed with ocular hypertension, a condition characterized by high eye pressure without confirmed optic nerve damage. The research examined these patient groups, often including them within the larger cohorts of the RCTs focused on glaucoma. The primary purpose of these studies was to monitor the change in IOP over the observation period.

The findings describe patterns observed in the studies regarding pressure measurements in the ocular hypertensive group. However, the evidence is largely focused on the pressure measurement as a primary outcome. The evidence contributes to understanding short-term outcomes in this specific population.

Long-Term Studies and Durability of IOP Measurements

The sustained nature of the IOP measurements was observed in various extended clinical research, with some studies monitoring patients for periods ranging from one to four years. These longitudinal studies monitored how the pressure measurements evolved in the observed populations to assess the continuation of the pattern observed in the short term.

What is Still Uncertain About Pentila

The research base, while extensive regarding IOP measurements, still contains several acknowledged limitations. The results apply only to the populations studied, and findings describe group patterns, not personal outcomes. Comparative evidence is lacking against some of the newest classes of glaucoma medications in recent, large-scale RCTs. Furthermore, evidence related to patient-reported outcomes describing perceived discomfort and overall quality of life is limited in comparison to the primary measurement of eye pressure.

Frequently Asked Questions (FAQ)

Common questions about Pentila (FAQ)


Q: How quickly does Pentila typically start to have an effect?

Regulatory labeling states that the pressure-lowering effect of the drug can be detected within one hour after the drops are administered. The maximum reduction in eye pressure is typically observed between two and six hours after the dose.

Q: How long does the effect of one dose of Pentila usually last?

Official information states that a significant decrease in intraocular pressure can be maintained for a period of up to 24 hours when the 0.5% concentration is used. The duration of effect is one factor that supports once-daily dosing patterns described in the product information.

Q: Are the side effects of Pentila usually mild?

Regulatory documents classify a range of possible effects. The most frequently reported side effects are localized events, such as eye irritation or pain. However, official warnings highlight the potential for less common, but more serious, systemic risks related to the heart and lungs that are typical of beta-blockers.

Q: Does Pentila interact with common over-the-counter pain medications?

The official product information does not list specific interactions with common over-the-counter (OTC) pain medications. However, official guidance emphasizes informing the prescribing healthcare professional about all prescription and non-prescription medicines.

Q: Can I take Pentila if I'm already taking supplements like vitamins?

Regulatory documents advise informing a healthcare professional about all products you are taking, which includes vitamins, nutritional supplements, and herbal products. This disclosure is important for the prescriber to monitor for potential effects.

Q: What is the list of ingredients in Pentila?

The active component is Levobunolol Hydrochloride. The medicine is supplied as a sterile ophthalmic solution, which contains this active ingredient dissolved in an aqueous vehicle. Regulatory documents also note that the solution contains the preservative sodium metabisulfite.

Q: Is Pentila suitable for use by older adults?

The medicine's use is established in the adult population. Official documents advise that caution may be necessary, as older patients may sometimes be more susceptible to certain systemic effects of beta-blockers.

Q: Does Pentila cause weight changes?

While sudden or major weight changes are not listed as a common side effect, official safety warnings mention monitoring for unusual or sudden weight gain. Official warnings note monitoring for unusual or sudden weight gain, as it may be an associated sign of a serious adverse reaction.

Q: Is Pentila known to cause dependence or addiction?

No. The active drug, Levobunolol Hydrochloride, is formally classified by major drug agencies as Not a controlled drug. The medicine is not associated with dependence or addiction.

Q: What should I do if I miss taking Pentila one day?

Official regulatory information states that a dose may be administered as soon as it is remembered. If it is close to the time of the next scheduled dose, the official document advises consulting the prescribing professional for guidance.

Q: Is Pentila an opioid or a controlled substance?

No, Pentila is not an opioid. The medication is formally classified as a beta-blocker and is designated as Not a controlled drug by regulatory agencies.

Q: What are the common signs of an allergic reaction to Pentila?

Signs of a serious allergic reaction, as described in official materials, may include rash, hives, or swelling of the face, tongue, or throat. Other severe symptoms include trouble breathing or severe dizziness.

Q: Can Pentila affect a person's ability to drive?

Official documentation indicates that the medicine may affect a person’s ability to drive. This warning is due to reported side effects such as temporary vision changes, dizziness, and confusion.

Q: What kind of monitoring might be needed while using Pentila?

Regular monitoring by an eye doctor is typically recommended to check eye pressure and eyesight. Additionally, monitoring may be necessary to check for unwanted systemic effects, such as changes to your heart rate and blood pressure.

Q: Is Pentila safe to stop using suddenly?

Regulatory documents describe a warning related to sudden discontinuation in certain patient populations. For patients with an overactive thyroid, abrupt cessation of the drug could potentially worsen the condition.

Q: Is Pentila a non-sedating medication?

Official side effect lists include reports of symptoms such as dizziness, confusion, and unusual drowsiness or dullness. These effects are listed in regulatory documents as adverse reactions related to the nervous system.

Q: Are there any long-term health concerns associated with using Pentila?

Regulatory sources specify that long-term use requires monitoring for potential serious systemic side effects. These include risks primarily related to cardiac health (e.g., cardiac failure) and respiratory function (e.g., bronchospasm) that are characteristic of beta-blockers.

Q: What age group was Pentila initially approved for?

The medicine's safety and effectiveness have been established only for the adult population. The documentation specifies that safety and effectiveness have not been established in the pediatric population.

Q: Does Pentila have a generic version available?

Yes. Regulatory records indicate that the FDA and other agencies have approved generic versions of the active ingredient, Levobunolol Hydrochloride.

Q: Are there different brand names for the same drug as Pentila?

Yes. The active ingredient in Pentila is Levobunolol Hydrochloride. Regulatory records identify Betagan as an example of another brand name that contains the same active ingredient.

Q: Is it normal to feel a change in appetite after starting Pentila?

This is not typically reported as a common side effect. However, some official lists of reported adverse events do include a lack of appetite, though this is classified as a less frequent or uncommon event.

How should Pentila be stored and disposed of?

How to Store and Dispose of Pentila

Official labeling for Pentila (Levobunolol Hydrochloride Ophthalmic Solution) requires adherence to specific storage and disposal rules to maintain product stability and safety.

Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, between 15°C and 25°C (59°F and 77°F).
Environmental Protection Protect from light; Do not freeze.
Container Keep the container tightly closed.
Child Safety Must be kept out of the reach of children.
Post-Opening Stability Discard the solution four weeks after first opening (for multi-dose bottles).

Disposal Instructions

Unused or expired Pentila must not be flushed down a sink or toilet. Disposal should follow guidelines for non-hazardous medicines, utilizing a drug take-back program when available. If a take-back program is unavailable, the contents should be removed from the container, mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pentila found in:

A-Z Index: